Citations

Clear

3942 citation(s) found for "To, Van".

THER-22. BROMODOMAIN INHIBITORS INDUCE DOWNREGULATION OF DNA DAMAGE REPAIR PATHWAYS AND OFFER NOVEL SYNERGISTIC COMBINATIONS WITH ENHANCED SAFETY PROFILES FOR THE TREATMENT OF MEDULLOBLASTOMA AND GLIOBLASTOMA
Lam, Fred C. , Vu‐Han, Tu‐Lan , Kooj, Bert Van de, Bandopadhayay, Pratiti , Kong, Yi Wen , Beroukhim, Rameen , Sarkaria, Jann N. , Hammond, Paula Therese , Yaffe, Michael B.

Mayo Clinic

Neuro-Oncology | April 23, 2019 | Volume: 21 | Issue: Supplement_2 | Pages: ii118-ii118

10.1093/neuonc/noz036.227 Get It

SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas.
Crowley, John, Movva, Sujana , Tine, Brian Andrew Van, Schuetze, Scott M. , Hu, James , Attia, Steven , Priebat, Dennis A., Okuno, Scott H. , Patel, Shreyaskumar , Baker, Laurence H. , Tawbi, Hussein, Burgess, Melissa , Reinke, Denise K. , Riedel, Richard F. , George, Suzanne , Davis, Lara E. , Reed, Damon R. , D'Angelo, Sandra P , Maki, Robert G.

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: TPS10578-TPS10578

10.1200/jco.2015.33.15_suppl.tps10578 Get It

A study of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft tissue sarcoma.
Chawla, Sant P. , Schöffski, Patrick , Attia, Steven , Tine, Brian Andrew Van, Patel, Shreyaskumar , Wagner, Andrew J. , Viele, James Kert, Cesne, Axel Le , Sankhala, Kamalesh K. , Falcone, Julianne, Schweizer, Charles, Weil, Susan C., Blay, Jean‐Yves , Jones, Robin L. , Gelderblom, Hans , Chmielowski, Bartosz , Trent, Jonathan C. , Chugh, Rashmi , Tinoco, Gabriel , Maki, Robert G.

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: TPS10577-TPS10577

10.1200/jco.2015.33.15_suppl.tps10577 Get It

A phase II study of tivozanib in patients with metastatic and non-resectable soft tissue sarcomas.
Agulnik, Mark , Rademaker, Alfred , Humphreys, Catherine, Abbinanti, Susan, Cehic, Rasima, Polish, Ariel, Vintilescu, Claudia Roxana, McFarland, Thomas, Okuno, Scott H. , Tine, Brian Andrew Van, Milhem, Mohammed , Humphreys, Catherine, Nye, Lauren Elizabeth , McFarland, Thomas, Skubitz, Keith M. , Robinson, Steven I.

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 10515-10515

10.1200/jco.2015.33.15_suppl.10515 Get It

Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women
Grant, Delores J. , Alberg, Anthony J. , Barnholtz‐Sloan, Jill S. , Bondy, Melissa L. , Funkhouser, Ellen, Moorman, Patricia G. , Peres, Lauren C. , Peters, Edward , Schwartz, Ann G. , Terry, Paul , Wang, Xin‐Qun, Hoyo, Cathrine , Sandler, Dale P. , Taylor, Jack A. , Edwards, Todd L., Beeghly‐Fadiel, Alicia, Wentzensen, Nicolas , Pearce, Celeste Leigh , Wu, Anna H. , Whittemore, Alice S. , McGuire, Valerie , Sieh, Weiva , Rothstein, Joseph H. , Ness, Roberta B., Moysich, Kirsten B. , Rossing, Mary Anne, Sellers, Thomas A. , Monteiro, Álvaro N.A. , Levine, Douglas A. , Haiman, Christopher A. , Menon, Usha , Ramus, Susan J. , Gayther, Simon A. , Terry, Kathryn L. , Goode, Ellen L. , Cannioto, Rikki , Odunsi, Kunle , Etter, John Lewis , Huang, Ruea‐Yea , Bernardini, Marcus Q. , Tone, Alicia , May, Taymaa, Goodman, Marc T. , Thompson, Pamela J., Carney, Michael E. , Tworoger, Shelley S. , Lambrechts, Diether , Vergote, Ignace , Nieuwenhuysen, Els Van , Salvensen, Helga B., Massuger, Leon F.A.G. , Bruegl, Amanda , Moffitt, Melissa , Le, Nhu D. , Brooks‐Wilson, Angela , Kelemen, Linda E. , Song, Honglin , Eccles, Diana , DeFazio, Anna , Kennedy, Catherine J. , Schildkraut, Joellen M. , Lambrechts, Diether , Barnholtz-Sloan, Jill S , Moysich, Kirsten , Permuth, Jennifer B , Cramer, Daniel W , Fazio, Anna de , Lambrechts, Diether , Ramus, Susan J , Sandler, Dale P , Tworoger, Shelley S , Eccles, Diana , Menon, Usha , Monteiro, Alvaro N , Brooks-Wilson, Angela R , Kennedy, Catherine J , Lambrechts, Diether , Sieh, Weiva , Taylor, Jack A , Goodman, Marc T , Manichaikul, Ani , Bandera, Elisa V. , Coté, Michele L. , Keku, Temitope O , Berchuck, Andrew , O’Brien, Katie M. , Edwards, Digna R. Velez , Beeghly‐Fadiel, Alicia , Modugno, Francesmary , Doherty, Jennifer A. , Permuth, Jennifer B. , Setiawan, Veronica Wendy , Marchand, Loı̈c Le , Wilkens, Lynne R. , Karlan, Beth Y. , Gentry‐Maharaj, Aleksandra , Cramer, Daniel W. , Larson, Melissa C. , Kaufmann, Scott H. , Poole, Elizabeth M. , Vanderstichele, Adriaan , Anton‐Culver, Hoda , Ziogas, Argyrios , Brenton, James D. , Bjørge, Line , Kiemeney, Lambertus A. , Pejovic, Tanja B. , Cook, Linda S. , Pharoah, Paul D.P. , Campbell, Ian

Mayo Clinic

Cancer Medicine | April 19, 2019 | Volume: 8 | Issue: 5 | Pages: 2503-2513

10.1002/cam4.1996 | PMID 31001917 Get It

AbstractAn association between genetic variants in the vitamin D receptor (VDR) gene and epithelial ovarian cancer (EOC) was previously reported in women of African ancestry (AA). We sought to examine associations between genetic variants in VDR and additional genes from vitamin D biosynthesis and pathway targets (EGFR, UGT1A, UGT2A1/2, UGT2B, CYP3A4/5, CYP2R1, CYP27B1, CYP24A1, CYP11A1, and GC). Genotyping was performed using the custom‐designed 533,631 SNP Illumina OncoArray with imputation to the 1,000 Genomes Phase 3 v5 reference set in 755 EOC cases, including 537 high‐grade serous (HGSOC), and 1,235 controls. All subjects are of African ancestry (AA). Logistic regression was performed to estimate odds ratios (OR) and 95% confidence intervals (CI). We further evaluated statistical significance of selected SNPs using the Bayesian False Discovery Probability (BFDP). A significant association with EOC was identified in the UGT2A1/2 region for the SNP rs10017134 (per allele OR = 1.4, 95% CI = 1.2‐1.7, P = 1.2 × 10−6, BFDP = 0.02); and an association with HGSOC was identified in the EGFR region for the SNP rs114972508 (per allele OR = 2.3, 95% CI = 1.6‐3.4, P = 1.6 × 10−5, BFDP = 0.29) and in the UGT2A1/2 region again for rs1017134 (per allele OR = 1.4, 95% CI = 1.2‐1.7, P = 2.3 × 10−5, BFDP = 0.23). Genetic variants in the EGFR and UGT2A1/2 may increase susceptibility of EOC in AA women. Future studies to validate these findings are warranted. Alterations in EGFR and UGT2A1/2 could perturb enzyme efficacy, proliferation in ovaries, impact and mark susceptibility to EOC.
Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn’s disease
Novak, Gregor , Stevens, Toer , Viegen, Tanja van, Bossuyt, Peter , Štabuc, Borut, Jeyarajah, Jenny , Zou, Guangyong , Gaemers, Ingrid C., McKee, Trevor D. , Fu, Fred , Shackelton, Lisa M. , Khanna, Reena , Sandborn, William J. , Feagan, Brian G. , Pai, Rish K. , D’Haens, Geert , Sandborn, W J , Feagan, B G , Vande Casteele, N , BRINK, Gijs R. VAN DEN , Jairath, Vipul , Casteele, Niels Vande , Zou, Guangyong , Bossuyt, Peter

Mayo Clinic

Alimentary Pharmacology & Therapeutics | April 15, 2019 | Volume: 49 | Issue: 11 | Pages: 1401-1409

10.1111/apt.15250 | PMID 30983024 Get It

SummaryBackgroundThe appropriate location for biopsy procurement relative to an ulcer in active Crohn's disease is unknown.AimTo explore the relationship between biopsy location, histological disease activity, proinflammatory gene expression and the presence of inflammatory cells.MethodsFifty‐one patients with Crohn's disease and ulcers >0.5 cm diameter in the colon and/or ileum were prospectively enrolled at three centres. Biopsies were obtained from 0 mm, 7 to 8 mm and 21 to 24 mm from the edge of the largest ulcer. Histological activity was blindly assessed with the Global Histological Disease Activity Score, the Robarts Histopathology and Nancy Histological indices. Messenger ribonucleic acid (mRNA) levels for interleukins‐6, ‐8 and ‐23 (p19 and p40 subunits), CD31 and S100A9 were measured using quantitative polymerase chain reaction. The number of CD3+, CD68+ and myeloperoxidase‐positive cells was quantified by immunohistochemistry. Data were analysed using mixed models with location and segment as fixed effects and patients as random effect to account for correlation among segments within a patient.ResultsHistological disease activity scores (P < 0.0001), proinflammatory gene expression levels (P < 0.005) and numbers of myeloperoxidase‐positive cells (P < 0.0001) were highest in biopsies from the ulcer edge in the colon and ileum, with decreasing gradients observed with distance from the edge (P < 0.05). No differences between colonic and ileal samples were detected for the parameters measured at any location.ConclusionsBiopsies from the ulcer edge in patients with Crohn's disease yielded the greatest histological disease activity and mRNA levels and had similar readouts in the colon and ileum. Research is needed to confirm this conclusion for other measures.
Epigenetics as a New Frontier in Orthopedic Regenerative Medicine and Oncology
Wijnen, André J. van , van Wijnen, Andre J , Westendorf, Jennifer J.

Mayo Clinic

Journal of Orthopaedic Research | April 12, 2019 | Volume: 37 | Issue: 7 | Pages: 1465-1474

10.1002/jor.24305 | PMID 30977555 Get It

ABSTRACTSkeletal regenerative medicine aims to repair or regenerate skeletal tissues using pharmacotherapies, cell‐based treatments, and/or surgical interventions. The field is guided by biological principles active during development, wound healing, aging, and carcinogenesis. Skeletal development and tissue maintenance in adults represent highly intricate biological processes that require continuous adjustments in the expression of cell type‐specific genes that generate, remodel, and repair the skeletal extracellular matrix. Errors in these processes can facilitate musculoskeletal disease including cancers or injury. The fundamental molecular mechanisms by which cell type‐specific patterns in gene expression are established and retained during successive mitotic divisions require epigenetic control, which we review here. We focus on epigenetic regulatory proteins that control the mammalian epigenome at the level of chromatin with emphasis on proteins that are amenable to drug intervention to mitigate skeletal tissue degeneration (e.g., osteoarthritis and osteoporosis). We highlight recent findings on a number of druggable epigenetic regulators, including DNA methyltransferases (e.g., DNMT1, DNMT3A, and DNMT3B) and hydroxylases (e.g., TET1, TET2, and TET3), histone methyltransferases (e.g., EZH1, EZH2, and DOT1L) as well as histone deacetylases (e.g., HDAC3, HDAC4, and HDAC7) and histone acetyl readers (e.g., BRD4) in relation to the development of bone or cartilage regenerative drug therapies. We also review how histone mutations lead to epigenomic catastrophe and cause musculoskeletal tumors. The combined body of molecular and genetic studies focusing on epigenetic regulators indicates that these proteins are critical for normal skeletogenesis and viable candidate drug targets for short‐term local pharmacological strategies to mitigate musculoskeletal tissue degeneration. © 2019 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 37:1465–1474, 2019.
Incremental costs of high intensive care utilisation in patients hospitalised with heart failure
Tran, Dat T. , Schnell, Gregory, Kaul, Padma , Diepen, Sean van , Ezekowitz, Justin A. , Wiley, Brandon M. , Morrow, David A. , McAlister, Finlay A.

Mayo Clinic

European Heart Journal: Acute Cardiovascular Care | April 12, 2019 | Volume: 8 | Issue: 7 | Pages: 660-666

10.1177/2048872619845282 | PMID 30977391 Get It

Aims: Registries have reported large inter-hospital differences in intensive care unit admission rates for patients with acute heart failure, but little is known about the potential economic impact of over-admission of low-risk patients with heart failure to higher cost intensive care units. We described the variability in intensive care unit admission practices, the provision of critical care therapies, and estimated the potential national cost savings if all hospitals adopted low intensive care unit admission practices for patients admitted with heart failure. Methods: Using a national population health dataset, we identified 349,693 heart failure admission hospitalisations with a primary diagnosis of heart failure between 2007 and 2016. Hospitals were categorised as low (first quartile), medium (second and third quartile) and high (fourth quartiles) intensive care unit utilisation. Results: The mean intensive care unit admission rate was 16.4% (inter-hospital range 0.3–51%) including 5.4% in low, 14.5% in medium and 30% in high utilisation hospitals. Intensive care unit therapies in low, medium and high intensive care unit utilisation hospitals were 54.5%, 45.1% and 24.1% ( P<0.001), respectively and the inhospital mortality rate was not significantly different. The proportion of hospital costs incurred by intensive care unit care was 7.8% in low, 19.8% in medium and 28.2% in high ( P<0.001) admission hospitals. The potential cost savings of altering intensive care unit utilisation practices for patients with heart failure was CAN$234.8m over the study period. Conclusions: In a national cohort of patients hospitalised with heart failure, we observed that low intensive care unit utilisation centres had lower hospital costs with no differences in mortality rates. The development of standardised admission criteria for high-cost and high acuity intensive care unit beds could reduce costs to the healthcare system.
Targeted Sequencing Study to Uncover Shared Genetic Susceptibility Between Peripheral Artery Disease and Coronary Heart Disease—Brief Report
Safarova, Maya , Fan, Xiao , Austin, Erin , Zuydam, Natalie Van, Hopewell, Jemma C. , Schaid, Daniel J. , Safarova, Maya S, Austin, Erin E, Hopewell, Jemma C , Kullo, Iftikhar J.

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | April 11, 2019 | Volume: 39 | Issue: 6 | Pages: 1227-1233

10.1161/atvbaha.118.312128 | PMID 31070467 Get It

Objective— It is unclear to what extent genetic susceptibility variants are shared between peripheral artery disease (PAD) and coronary heart disease (CHD), both manifestations of atherosclerotic vascular disease. We investigated whether common and low-frequency/rare variants in loci associated with CHD are also associated with PAD. Approach and Results— Targeted sequencing of 41 genomic regions associated with CHD in genome-wide association studies was performed in 1749 PAD cases (65±11 years, 61% men) and 1855 controls (60±11 years, 56% men) of European ancestry. PAD cases had a resting/postexercise ankle-brachial index ≤0.9, or history of lower extremity revascularization; controls had no history of PAD. We tested the association of common (defined as minor allele frequency ≥5%) variants with PAD assuming an additive genetic model with adjustment for age and sex. To identify low-frequency/rare variants (minor allele frequency <5%) associated with PAD, we conducted gene-level analyses using sequence kernel association test and permutation test. After Bonferroni correction, we found common variants in SH2B3, ABO , and ZEB2 to be associated with PAD ( P <4.5×10 −5 ). At the gene level, the strongest associations were for LPL and SH2B3 . Conclusions— Targeted sequencing of 41 genomic regions associated with CHD revealed several common variants/genes to be associated with PAD, highlighting the basis of shared genetic susceptibility between CHD and PAD.
Wide local excision prior to sentinel lymph node biopsy for primary melanoma of the head and neck
May, Matthew M. , Lohse, Christine M. , Moore, Eric J. , Abel, Kathryn M. Van , Brewer, Jerry D., Janus, Jeffrey R. , Van Abel, Kathryn M , Price, Daniel L.

Mayo Clinic

International Journal of Dermatology | April 10, 2019 | Volume: 58 | Issue: 10 | Pages: 1184-1190

10.1111/ijd.14435 | PMID 30968948 Get It

AbstractBackgroundPrevious wide local excision prior to sentinel lymph node biopsy (SLNB) may have the potential to disrupt lymphatic channels, thus incorrectly identifying the sentinel node. The purpose of this study was to investigate: (1) regional recurrence rates of prior wide local excision compared to other biopsy techniques and (2) survival outcomes in patients with melanoma of the head and neck.MethodsBetween the years 2000 and 2016, 391 cases were reviewed with a median follow‐up time of 30 months in a large tertiary care center. Biopsy practices included shave, punch, wide local excision, and narrow margin excisional/Mohs, and associations with time to local or regional relapse and death from melanoma were evaluated. Main outcomes included identification of sentinel lymph nodes, overall survival, and melanoma‐specific survival.ResultsOf the 391 patients, biopsy patterns were as follows: 77 (19%) unknown biopsy, 30 (8%) prior wide local excision (WLE), 105 (27%) narrow margin excisional biopsy, 69 (18%) punch biopsy, and 110 (28%) shave biopsy. SLNB was successfully identified in all 30 patients whom had a prior WLE. There were 50 regional recurrences in the neck and 27 local recurrences with the median (IQR) at 1.2 years and 1.0 years, respectively. Multivariable associations of type of prior biopsy, depth of invasion, and nodal status with time to regional recurrence, local recurrence, overall survival, and melanoma‐specific survival were not significantly different.ConclusionsSentinel lymph node biopsy for melanoma of the head and neck can be successfully performed in patients after previous wide local excision.